Clients

Genedrive plc

Jan 29, 2021, 13:50 PM
Company EPIC Code : AIM: GDR
Company Name : Genedrive plc
Company Sector : Pharmaceuticals and Biotechnology (Biotechnology)
Venue : At 46 Grafton Street, Manchester M13 9XX
Event Date : Dec 30, 2024, 10:00 AM

Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications.

The Company has assays on the market for the detection of MT-RNR1, HCV, certain military biological targets, a high throughput SARS-CoV-2 assay and a point of care test for Covid-19.

The company are currently developing a genetic test for CYP2C19 metaboliser status.

Management will hold the company’s AGM on Monday, 30 December 2024

The Company’s 2024 Annual Report and Accounts are now available on the Company's website  http://www.genedriveplc.com/investor-relations/company-reports.php

Monday, 30 December 2024 at 10am

 Event Date
Year End30 June
Half  Year End31 December
Preliminary ResultsNovember
Interim Results*March
AGM*December

* Months based on previous announcements of this kind

Genedrive plc genedrive Prelims ppt - 2 Dec 2024 Investment_Summary
Load more comments
Thank you for the comment! Your comment must be approved first
avatar
New code

Who We Work With

Genedrive plc

Jan 29, 2021, 13:50 PM
Company EPIC Code : AIM: GDR
Company Name : Genedrive plc
Company Sector : Pharmaceuticals and Biotechnology (Biotechnology)
Venue : At 46 Grafton Street, Manchester M13 9XX
Event Date : Dec 30, 2024, 10:00 AM

Genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications.

The Company has assays on the market for the detection of MT-RNR1, HCV, certain military biological targets, a high throughput SARS-CoV-2 assay and a point of care test for Covid-19.

The company are currently developing a genetic test for CYP2C19 metaboliser status.

Management will hold the company’s AGM on Monday, 30 December 2024

The Company’s 2024 Annual Report and Accounts are now available on the Company's website  http://www.genedriveplc.com/investor-relations/company-reports.php

Monday, 30 December 2024 at 10am

 Event Date
Year End30 June
Half  Year End31 December
Preliminary ResultsNovember
Interim Results*March
AGM*December

* Months based on previous announcements of this kind

Genedrive plc genedrive Prelims ppt - 2 Dec 2024 Investment_Summary
Load more comments
Thank you for the comment! Your comment must be approved first
avatar
New code